Dare Bioscience (DARE) Reports In-Line Q2 EPS

Dare Bioscience (NASDAQ: DARE) reported Q2 EPS of ($0.10), in-line with the analyst estimate of ($0.10).

For earnings history and earnings-related data on Dare Bioscience (DARE) click here.

You May Also Be Interested In

• Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances
• KULR Technology Group (KULR) Misses Q2 EPS by 39c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c